Research Article
Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
Table 1
Demographic characteristics at baseline.
| Baseline characteristics | Teriflunomide | Glatiramer acetate | value |
| Patients | 29 | 30 | | Mean age, years (SD) | 57.9 (7.6) | 52.4 (11.3) | 0.03 | Median age (years) | 59.3 | 55.8 | | Female % () | 58.6 (17) | 66.7 (20) | 0.71 | SPMS % () | 96.6 (28) | 86.7 (26) | | Mean disease duration, years (SD) | 16.7 (9.5) | 15.1 (10.4) | 0.54 | Median disease duration (years) | 14.4 | 12.6 | | Mean treatment duration, months (SD) | 32.4 (13.6) | 46.9 (43.9) | 0.09 | Median treatment duration, months (SD) | 32.9 | 34.2 | | EDSS mean (SD) | 5.9 (1.3) | 5.7 (1.6) | 0.58 | EDSS median | 6 | 6 | | T25FW mean, seconds (SD) | 10.3 (5.7) | 15.3 (13.6) | 0.11 | T25FW median, seconds | 8.1 | 11.6 | |
|
|
SPMS: secondary progressive multiple sclerosis; EDSS: expanded disability status scale; T25FW: timed 25-foot walk; SD: standard deviation; : number of subjects. |